July - 2020

MECFA Blog

Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibro

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a key opinion leader webinar today at 12:00...

AzurRx Begins Phase 2b Trial Testing MS1819 for Pancreatic Insufficiency in CF Patients

AzurRx BioPharma has launched a Phase 2b clinical trial investigating its MS1819 as a potential treatment for exocrine pancreatic...

Smoking, Respiratory Issues, Older Age Raise Hospital Costs, Chinese Study Finds

Older age, smoking, and having other respiratory symptoms and conditions increase the hospitalization costs of people with...

Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronc

--Brensocatib Shown to Reduce Time to First Pulmonary Exacerbation and Reduce Rate of Exacerbations Versus Placebo-- --New Data...

World-first clinical trial raises hopes of new drug for chronic lung disease

CHRONIC lung disease sufferers could be aided by a new drug which helps reduce the need for antibiotics, according to a clinical trial....

The Multidisciplinary Team Improves Cystic Fibrosis Outcomes

CYSTIC FIBROSIS (CF) is an inherited autosomal recessive disease, and it affects approximately 30,000 Americans. Chronic, progressive,...

Women With CF Use Combined Hormonal Contraceptives More Than Other Methods, Study Reports

Among women of childbearing age with cystic fibrosis (CF), the use of combined hormonal contraceptives containing both estrogen and...

Drying Does Not Clear Nebulizers of NTM Bacteria, Study Finds

Nontuberculous mycobacteria (NTM), a type of infectious bacteria, is able to survive being dried for a full day, a study found,...

CHMP Gives Positive Opinion to Vertex’s Triple Combination Therapy Kaftrio

The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in...

Brensocatib prolongs time to first pulmonary exacerbation in patients with bronchiectasis

Treatment with brensocatib for 24 weeks significantly prolonged time to first pulmonary exacerbation in patients with non-cystic fibrosis...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p